Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049031 | 0.94 | CHEK1 (0.45) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL7046842 | 0.91 | MAPK1 (0.48) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL7048583 | 0.73 | NPSR1 (0.48) | ATRMAPK1NPSR1MTORMAPT | |
| SCHEMBL7045657 | 0.73 | NPSR1 (0.48) | MAPK1NPSR1MTORMAPTCYP1A2 | |
| SCHEMBL7458020 | 0.67 | MTOR (0.50) | ATRATRIPMAPK1NPSR1MTOR | |
| SCHEMBL20651545 | 0.63 | CHEK1 (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| 1-Methylimidazole SCHEMBL1889707 | 0.63 | NFKB1 (0.48) | MAPTCYP1A2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6694832 | 0.62 | SMN1; SMN2 (0.41) | MAPK1NPSR1MAPTCYP1A2CYP2C9 | |
| SCHEMBL28747262 | 0.62 | NPSR1 (0.35) | MAPK1NPSR1MAPTALDH1A1 | |
| SCHEMBL6960039 | 0.61 | GRIA1 (0.36) | MAPK1NPSR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-6599911-B2 | Particularly useful in treating and suppressing human Cytomegalovirus | TULARIK INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030045715-A1 | Arylsulfonic acid salts of pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6410726-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | ATR 670/4885ATRIP 2583/4885CHEK1 553/4885 |
| US-20030045715-A1 | Arylsulfonic acid salts of pyrimidine-based antiviral agents | PNP, TPMT, NSUN2 | ATR 166/4885ATRIP 1041/4885CHEK1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.